Addus HomeCare price target raised to $145 from $140 at Oppenheimer

Oppenheimer raised the firm’s price target on Addus HomeCare to $145 from $140 and keeps an Outperform rating on the shares after hosting meetings with management and as the firm remains bullish on the story heading into year-end. Overall, Addus is seeing improving operating trends, as turnover and productivity continue to rebound from the pandemic-era lows, Oppenheimer says. Meanwhile, Addus remains optimistic around the M&A pipeline, with the Gentiva deal slated to close in Q4 2024. Overall, the firm continues to believe that Addus is attractively positioned, and would continue to be a long-term buyer.